Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
Clinical trial NCT02287428 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02287428
- Sponsor
- Dana-Farber Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-11-01
- Primary completion
- 2027-02-01
- Enrollment
- 56
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.